Wilson disease;Morbus Wilson

Internist

Volumn 46, Issue 7, 2005, Pages 731-740

  Huster, D ^a,b   Kuhn H J ^a   Mossner J ^a   Caca, K ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

ATP7B; Central nervous system; Copper; Liver toxicity; Wilson disease

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CARRIER PROTEIN; CHELATING AGENT; HISTIDINE ZINC; IMMUNOSUPPRESSIVE AGENT; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; UNCLASSIFIED DRUG; ZINC ACETATE; ZINC DERIVATIVE; ZINC SULFATE;

APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOSOMAL RECESSIVE INHERITANCE; CHRONIC HEPATITIS; CLINICAL TRIAL; COPPER METABOLISM; DIAGNOSTIC TEST; DYSARTHRIA; GENE MUTATION; GENE THERAPY; HEPATOCYTE TRANSPLANTATION; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; MENTAL DISEASE; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; PATHOGENESIS; PROGNOSIS; SYMPTOMATOLOGY; TOXICITY; TREATMENT OUTCOME; TREMOR; WILSON DISEASE;

ADENOSINE TRIPHOSPHATASES; CATION TRANSPORT PROTEINS; CHELATING AGENTS; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NERVOUS SYSTEM DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 22144460967     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1432-7     Document Type: Article

References (30)

1. Brewer GJ (2000) Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med 223: 39-46
2. Schumann K, Classen HG, Dieter HH et al. (2002) Hohenheim consensus workshop: copper. Eur J Clin Nutr 56: 469-483
3. Tapiero H, Townsend DM, Tew KD (2003) Trace elements in human physiology and pathology. Copper. Biomed Pharmacother 57: 386-398
4. Roberts EA, Cox DW (1998) Wilson disease. Baillieres Clin Gastroenterol 12: 237-256
5. Shim H, Harris ZL (2003) Genetic defects in copper metabolism. J Nutr 133: 1527S-1531S
6. Strausak D, Mercer JF, Dieter HH, Stremmel W, Multhaup G (2001) Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull 55: 175-185
7. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV (1999) Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284: 805-808
8. Field LS, Luk E, Culotta VC (2002) Copper chaperones: personal escorts for metal ions. J Bioenerg Biomembr 34: 373-379
9. Lutsenko S, Efremov RG, Tsivkovskii R, Walker JM (2002) Human copper-transporting ATPase ATP7B (the Wilson's disease protein): biochemical properties and regulation. J Bioenerg Biomembr 34: 351-362
10. Hoogenraad TU (2001) Wilson's disease. Intermed Medical Publishers, Amsterdam
11. Bearn AG (1953) Genetic and biochemical aspects of Wilson's disease. Am J Med 15: 442-449
12. Schilsky ML (1996) Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis 16: 83-95
13. Brewer GJ (2001) Wilson's disease. A clinician's guide to recognicion, diagnosis, and management. Kluwer Academic, Boston Dordrecht London
14. Tsivkovskii R, Efremov RG, Lutsenko S (2003) The role of the invariant His1069 in folding and function of the Wilson's disease protein, the human copper-transporting ATPase ATP7B. J Biol Chem 278: 13.302-13.308
15. Huster D, Hoppert M, Lutsenko S et al. (2003) Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology 124: 335-345
16. Forbes JR, Cox DW (2000) Copper-dependent trafficking of wilson disease mutant ATP7B proteins. Hum Mol Genet 9: 1927-1935
17. Forbes JR, Cox DW (1998) Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 63: 1663-1674
18. Caca K, Ferenci P, Kuhn HJ et al. (2001) High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol 35: 575-581
19. Cox D, Prat L, Walshe JM, Roberts EA, Bilodeau M (2003) The impotance of molecular diagnosis for Wilson Disease. Hepatology 38: 230A
20. Ferenci P (2004) Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 19: 229-239
21. Roberts EA, Schilsky ML (2003) A practice guideline on Wilson disease. Hepatology 37: 1475-1492
22. Langner C, Denk H (2004) Wilson disease. Virchows Arch 445: 111-118
23. Ferenci P, Caca K, Loudianos G et al. (2003) Diagnosis and phenotypic classification of Wilson disease. Liver 23: 139-142
24. Sturniolo GC, Mestriner C, Irato P, Albergoni V, Longo G, D'Inca R (1999) Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am J Gastroenterol 94: 334-338
25. Siegemund R, Gunther K, Kuhn HJ, Lossner J (1988) Medikamentöse Beeinflussung der Bioverfügbarkeit von Kupfer. Zentralbl Pharmakol Pharmakother Labordiagnostik 127: 239-240
26. 64copper with copper balance. Am J Med Sci 292: 344-349
27. Schumacher G, Platz KP, Mueller AR et al. (1997) Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. Clin Transplant 11: 217-224
28. Geissler I, Heinemann K, Rohm S, Hauss J, Lamesch P (2003) Liver transplantation for hepatic and neurological Wilson's disease.Transplant Proc 35: 1445-1446
29. Irani AN, Malhi H, Slehria S, Gorla GR, Volenberg I, Schilsky ML, Gupta S (2001) Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson's disease. Mol Ther 3: 302-309
30. Ha-Hao D, Merle U, Hofmann C et al. (2002) Chances and shortcomins of adenovirus-mediated ATP7B gene transfer in Wilson disease: proof of principle demonstrated in a pilot study with LEC rats. Z Gastroenterol 40: 209-216